Dare Bioscience (DARE) Non-Current Debt (2013 - 2016)
Dare Bioscience's (DARE) quarterly Non-Current Debt came in at $4.4 million in Q4 2016, down 64.97% YoY from $12.7 million in Q1 2016, and down 32.23% on a QoQ basis from $6.6 million in Q3 2016.
Dare Bioscience (DARE) Non-Current Debt (2013 - 2016) Analysis & Trends
Dare Bioscience (DARE) has 4 years of Non-Current Debt data on file, last reported at $4.4 million in Q4 2016.
- Quarterly Non-Current Debt fell 64.97% year-over-year to $4.4 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $4.4 million (down 64.97% YoY) and the FY2016 annual result came in at $4.4 million, down 64.97% from the prior year.
- Non-Current Debt retreated to $4.4 million in Q4 2016, from $6.6 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $13.6 million in Q1 2015 to a low of $587000.0 in Q3 2014.
- A 4-year average of $7.2 million and a median of $7.6 million in 2016 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2015 — Non-Current Debt jumped 1693.87% — and 2016, when it slumped 64.97%.
- Tracing DARE's Non-Current Debt over 4 years: stood at $3.1 million in 2013, then slumped by 81.21% to $587000.0 in 2014, then surged by 2058.77% to $12.7 million in 2015, then tumbled by 64.97% to $4.4 million in 2016.
- The last three Non-Current Debt figures came in at $4.4 million (Q4 2016), $6.6 million (Q3 2016), and $8.6 million (Q2 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 8.96 Bn |
| 10 | Dare Bioscience | 12.39 Mn | -230,742.75 | -132,343.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 4.44 Mn |
| Sep 30, 2016 | 6.55 Mn |
| Jun 30, 2016 | 8.65 Mn |
| Mar 31, 2016 | 10.69 Mn |
| Dec 31, 2015 | 12.67 Mn |
| Sep 30, 2015 | 10.53 Mn |
| Jun 30, 2015 | 11.83 Mn |
| Mar 31, 2015 | 13.58 Mn |
| Sep 30, 2014 | 587,000.00 |
| Jun 30, 2014 | 1.45 Mn |
| Mar 31, 2014 | 2.30 Mn |
| Dec 31, 2013 | 3.12 Mn |